527 results on '"Springfeld, Christoph"'
Search Results
2. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data
3. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response
4. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
5. Aktuelle systemische Therapie beim Pankreaskarzinom
6. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial
7. A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
8. Neoadjuvant therapy for pancreatic cancer
9. Deep Learning–Enabled Diagnosis of Liver Adenocarcinoma
10. Surgical management of primary liver cancers during the COVID-19 pandemic: overcoming the dilemma with standardization
11. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
12. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis
13. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma
14. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
15. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
16. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery
17. The Evolution of Adjuvant Trials in Pancreatic Cancer
18. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
19. ESMO 2023 pancreatic cancer guidelines signal stepwise progress
20. Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival
21. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities
22. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease
23. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
24. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
25. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
26. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?
27. Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
28. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma
29. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma
30. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
31. Chemotherapy for pancreatic cancer
32. Community-driven development of a modified progression-free survival ratio for precision oncology
33. Promising Outcomes of Modified ALPPS for Staged Hepatectomy in Cholangiocarcinoma
34. Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
35. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
36. Location of tissue associated macrophages M2 in pancreatic cancer
37. Safety of multimodality treatment with a combination of intra- operative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: The combiCaRe study
38. Personalized treatment in localized pancreatic cancer
39. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis
40. Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer
41. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma
42. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
43. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
44. Palliative Chemotherapy for Advanced Pancreatic Cancer
45. Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition
46. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study
47. Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients
48. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
49. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
50. Supplementary Patient Data from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.